Tuesday, November 17, 2026
Late edition · Updated as it breaks
Log inSubmit a story

“All the news worth catching.”

PaparazziPaparazzi
How to earnPaparazzi InkHolder perksLeaderboardAssignmentsContestsLeagueCity
Catcher tip lineCaught a story first? Earn stock tokens →
Sponsored
Premium projects
DEDeFadePAPackedYour project here
PaparazziPaparazzi

All the news worth catching.

Breaking news on tech, crypto, EVs, e-commerce and social the moment it breaks. Written by AI from verified reporting.

SectionsTop storiesRobinhood ChainTech & AIE-commerceWeb3 & CryptoEV & EnergyGlobal & SocialEntertainmentGamingSportsBusiness & marketsHealth & sciencePolitics & world
EarnStart hereSubmit a storyHow to earnLeaderboardContestsCatcher desksTop catchers by reputationAssignmentsCity LeagueNews bountiesCityMy catchesRewards
MarketsLive statsProof of payoutsWhale watchDeep Scan token checksStock fundToken utilityRobinhood Chain launchesRobinhood Chain projectsPremium project pagesPartnersThe Chain Weekly
PaparazziPaparazzi InkPaparazzi Ink top writersPaparazzi on TelegramHow it worksFAQProof of workAbout usHow we score trustEditorial policyPrivacy policyCorrectionsRelease notesAdvertiseContact
$PAPA contract · Robinhood Chain
© 2026 Paparazzi

Written by AI from verified reporting. Not financial advice.

  • Home
  • Submit
  • Earn
  • Sign in
Top storiesRobinhood ChainTech & AIE-commerceWeb3 & CryptoEV & EnergyGlobal & SocialEntertainmentGamingSportsBusiness & marketsHealth & sciencePolitics & worldWhales
Health & science
Important· 55
Confirmed by 3 outlets

FDA Rejects Summit's Ivonescimab for EGFR-Mutant Lung Cancer

The FDA slapped Summit Therapeutics with a complete response letter for ivonescimab plus chemotherapy in EGFR-mutated NSCLC, saying the trial's progression-free survival win wasn't enough without a statistically significant overall survival gain. It's a blow for the first PD-1 x VEGF bispecific aiming at a US approval, though ivonescimab is already cleared in China.

By the Paparazzi desk November 15, 2026 · 3:19 PM · Sources: 3 outlets · 0 views
Fact boxTrust 66/100 · Developing
What we verified
  • 3 sources report it: targetedonc.com, oncodaily.com, cancernetwork.com.
  • The source published it on Nov 15, 2026 at 3:19 PM.
What we couldn't

Nothing open. Every check passed.

The FDA handed Summit Therapeutics a complete response letter for its biologics license application covering ivonescimab combined with platinum-based chemotherapy. The drug was aimed at patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer whose disease progressed after EGFR tyrosine kinase inhibitor therapy. Regulators told Summit that substantial evidence of effectiveness wasn't established because overall survival didn't improve by a statistically significant margin, and that the progression-free survival benefit alone didn't support a positive benefit-risk profile.

The application rested on the global phase 3 HARMONi trial, which enrolled 438 adults at 114 centers across North America, Europe and Asia. Adding ivonescimab to carboplatin and pemetrexed pushed median progression-free survival by independent review to 6.8 months, versus 4.4 months for chemotherapy alone, with a hazard ratio of 0.52 and a P value under .0001. Overall survival, though, landed at 16.8 months against 14.0 months at the primary analysis, a hazard ratio of 0.79 with P = .057 — close, but not statistically significant.

Sponsored

Summit didn't go down quietly. An updated post hoc overall survival analysis, announced in July 2026 and presented at the 2026 World Conference on Lung Cancer, extended follow-up to a June 2026 cutoff across the whole population at a median of 29.9 months. Median overall survival held at 16.8 versus 14.0 months, with a hazard ratio of 0.76 and a nominal P = .0151. In the Western cohort of 165 patients enrolled in North America and Europe, median overall survival was 17.5 months versus 14.0 months at a median follow-up of 23.2 months, with a hazard ratio of 0.76.

Safety data showed treatment-related adverse events in 95.0% of ivonescimab patients versus 93.1% on placebo, with grade 3 or higher events in 50.0% versus 42.2% and serious adverse events in 28.0% versus 15.1%. The most common events on ivonescimab were anemia at 49.1%, decreased white blood cell count at 45.0%, decreased neutrophil count at 42.7% and decreased platelet count at 32.6%. Hemorrhage occurred in 10.6% of ivonescimab patients, with grade 3 or higher bleeding in 0.9%.

Robert W. Duggan, Summit's chairman and co-chief executive officer, said the company was disappointed for patients and families awaiting new options in this setting, adding that Summit pursued the regimen to offer another treatment choice. Summit also pointed out that no FDA-approved regimen has demonstrated a statistically significant overall survival benefit in this patient population. Ivonescimab remains investigational in the United States and Europe, and no PD-1 x VEGF bispecific antibody is approved in the US.

Elsewhere the picture looks brighter. A separate phase 3 trial in China, HARMONi-A, showed a statistically significant overall survival benefit in a similar population and led to ivonescimab's approval there in May 2024. Ivonescimab has been tested or is being tested in 14 phase 3 trials, 10 based in China and 4 global, including HARMONi-2, where it extended survival versus pembrolizumab in first-line PD-L1-positive NSCLC, and HARMONi-GI1, where it beat durvalumab plus chemotherapy in biliary tract cancer. Duggan nodded to that record: five positive phase 3 studies between Summit and Akeso, he said, leave the company's belief in ivonescimab unchanged.

Price since story
RKLB-6.61%
Market data, not advice.

TopicsFDA · Summit Therapeutics · ivonescimab · Akeso · Robert W. Duggan · HARMONi trial · pembrolizumab · durvalumab

Share

Written by AI from verified reporting. Not financial advice.

More stories

  • Health & science 52 minutes ago · finance.yahoo.com · 0 views
    Novartis' Cosentyx wins FDA nod as first anti-IL-17 biologic for PMR
  • Health & science 3 hours ago · casrai.org · 0 views
    FDA greenlights giredestrant-everolimus duo for ESR1-mutated breast cancer
  • Health & science 4 hours ago · nbcnews.com · Caught by @nina.anggraini29 · 0 views
    Measles Is Endemic Again as the U.S. Loses Its Elimination Status
  • Health & science 4 hours ago · aol.com · 1 view
    FDA Clears FoundationOne Liquid CDx as First Companion Test for WILSERDLY Combo
Catcher tip line

Caught a story we missed?

Log in and send it in. If it checks out, it runs with your name on it and you earn stock tokens. The bigger the story, the bigger the reward.

Submit a story
The newsletter

Get the paper in your inbox.

A short digest of the biggest news, plus optional breaking alerts. Free, no account needed.